A5071018801- Thyroid and Parathyroid Surgery
- Pharmaceutical studies and practices
- Parathyroid Disorders and Treatments
- Genetic Syndromes and Imprinting
- Bone health and treatments
- Digestive system and related health
- Bone health and osteoporosis research
- Diet and metabolism studies
- Proteins in Food Systems
- Clinical Nutrition and Gastroenterology
- Gastroesophageal reflux and treatments
- Growth Hormone and Insulin-like Growth Factors
- Cholinesterase and Neurodegenerative Diseases
- Bone Metabolism and Diseases
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Metabolism, Diabetes, and Cancer
- Protein Hydrolysis and Bioactive Peptides
- Advanced Drug Delivery Systems
Enter (Switzerland)
2014-2017
Hebrew University of Jerusalem
2013
Anabolic treatment is indicated for high and very-high risk patients with osteoporosis, but acceptance limited because current anabolic medications require subcutaneous injections. The purpose of this study was to assess the effects a novel orally administered PTH tablet on serum markers bone formation (PINP osteocalcin), resorption (crosslinked C-telopeptide [CTX]), BMD, safety in postmenopausal women low BMD or osteoporosis. In 6-mo, double-blind, placebo-controlled study, 161 were...
ABSTRACT The standard treatment of primary hypoparathyroidism (hypoPT) with oral calcium supplementation and calcitriol (or an analog), intended to control hypocalcemia hyperphosphatemia avoid hypercalciuria, remains challenging for both patients clinicians. In 2015, human parathyroid hormone (hPTH) (1-84) administered as a daily subcutaneous injection was approved adjunctive in who cannot be well controlled on the treatments alone. This open-label study aimed assess safety efficacy...
Oral delivery of peptides and proteins is hindered by their rapid proteolysis in the gastrointestinal tract inability to permeate biological membranes. Various drug approaches are being investigated implemented overcome these obstacles. In discussed study conducted pigs, an investigation was undertaken assess effect combination a permeation enhancer - salcaprozate sodium, inhibitor soybean trypsin inhibitor, on systemic exposure peptide teriparatide, following intraduodenal administration....
During recent years there has been increasing interest in the <i>Lycopodium</i> alkaloid huperzine A as a potential therapeutic agent for neurodegenerative diseases. This study aimed to characterize A's permeability across enterocyte barrier along gastrointestinal tract with an emphasis on effect of ionization drug absorption. Intestinal was evaluated by <i>in vitro</i> Caco-2 and parallel artificial membrane permeation assay models <i>ex vivo</i> Ussing chamber model. The rate strongly...